Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (OTCPK:AZNCF)

AstraZeneca Updates on Immuno-Oncology Combinations Development Program at ASCO 2015

Business Wire June 2, 2015

Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum

PR Newswire June 2, 2015

AstraZeneca Presents Positive Data on AZD9291 in First-Line EGFR Mutated Lung Cancer at ASCO 2015

Business Wire May 31, 2015

AstraZeneca and MedImmune Present Positive Immuno-Oncology Combination Data at ASCO 2015

Business Wire May 30, 2015

Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors

PR Newswire May 29, 2015

Olympic Gold Medalist Jackie Joyner-Kersee Teams up with AstraZeneca to Raise Awareness about Opioid-Induced Constipation

Business Wire May 20, 2015

MOVANTIKTM (naloxegol) Safety Analyses of Opioid-Induced Constipation Patients 65 and Older with Chronic Non-Cancer Pain

Business Wire May 16, 2015

AstraZeneca to Update on Progress with Immuno-Oncology Pipeline and Combination Treatments at ASCO 2015

Business Wire May 13, 2015

US FDA Grants Priority Review for Potential New Indication for BRILINTA

Business Wire April 29, 2015

Bina Technologies and AstraZeneca Announce Collaborative Agreement for Global Deployment of Bina's Genomic Management Solution

Business Wire April 21, 2015

PatientsLikeMe and AstraZeneca Announce Global Research Collaboration

Business Wire April 13, 2015

BRILINTA Receives US FDA Approval for New Administration Option

Business Wire March 30, 2015

Maryland Regional Biotech Forum Aims to Propel Washington, D.C. Metro Region to a Top Three Ranked U.S. Biotech Hub by 2023

Business Wire March 30, 2015

PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

Business Wire March 14, 2015

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

Business Wire January 29, 2015

Pharmaceutical-Bio Industry's First-Quarter 2015 Capital and Maintenance Project Starts Near $4 Billion Investment in North America, an Industrial Info News Alert

Marketwired January 20, 2015

PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses

Business Wire January 14, 2015

U.S. Mid-Atlantic to See More Than $9 Billion in Projects Begin Construction in First-Quarter 2015, an Industrial Info News Alert

Marketwired January 12, 2015

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1(TM) Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

PR Newswire December 11, 2014

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

PR Newswire November 25, 2014